Oncogene-addicted non-small cell lung cancer (NSCLC) patients have been witnessing overwhelming therapeutic improvements, especially in advanced disease management, due to the advent of more potent tyrosine kinase inhibitors (TKIs). However, the concrete chance to cure anaplastic lymphoma kinase (ALK)-rearranged patients remains prerogative of surgical and peri-operative medical approaches to early disease stage. Clinical investigations in the adjuvant setting of genotype-restricted lung cancers (i.e., EGFR+, ALK+, etc.) are under-represented owing to the need of large patients' enrollment and solid overall survival (OS) data, which solely can show real long-term impact of these therapeutic interventions. Current available radiological and molecular technologies will widely increase the number of surgical early stage patients, including ALK+, spurring the development of rational approaches aimed to prevent disease recurrence and prolong patients' survival. Ongoing clinical trials, evaluating crizotinib and alectinib as adjuvant treatments, will gauge the real impact of TKIs in terms of patients' disease free survival (DFS) and OS; other peri-operative investigations (e.g., neo-adjuvant strategies) will add information about ALK inhibitors' tumor growth restraint capacities and early adaptation mechanisms to ALK targeting. Nevertheless, multiple questions are and will remain unanswered: if should be treated indifferently all ALK+ patients or, alternatively, should be stratified in different risk groups based on the detectable residual disease [i.e., minimal residual disease (MRD) after surgery]; whether ALK inhibitors administration could facilitate the accumulations of persister cells driving resistance mechanisms to targeted therapies; if alternative strategies, as combined treatments targeting different molecular hubs, could enhance disease control and cancer eradication.
Introduction
Anaplastic lymphoma kinase (ALK) targeting has been, undoubtedly, one of the most revolutionized fields among oncogene-addicted lung cancer patients. In the recent years we can number clinical trials, such as phase 3 randomized ALEX and ALTA-1L, which represent huge milestones in the therapeutic management of advanced ALK+ non-small cell lung cancer (NSCLC) patients (1, 2) . Both these trials evaluated the activity of a second-generation tyrosine kinase inhibitor (TKI), respectively alectinib for ALEX and brigatinib for ALTA-1L, compared to first-generation TKI, crizotinib, the gold standard therapeutic choice for these patients (1) (2) (3) . Indeed, more potent ALK inhibitors (ALKi) have been showing deeper and more durable disease control, leading to results hardly imaginable before S291 [i.e., median progression-free survival (PFS) of 34.8 months for patients receiving alectinib versus 10.9 crizotinib] (4) . Based on these data, alectinib has been approved as first-line treatment option for ALK+ NSCLC patients and, likely, other actors will play major role in the upfront management of these patients.
Despite these improvements in the advanced setting, a thick fog of uncertainty wraps around the role of ALK-targeting in early/locally advance stage of the disease and whether ALKi play any role in this scenario still remains vague. Therefore, ALK rearrangements are not routinely screened in patients' specimens at these disease stages, unless required when enrolled within specific clinical trials (5) .
In early stages NSCLC, surgery still represents the potentially curative approach, aimed to eliminating all the radiological detectable tumor bulk. However, a large fraction of patients, roughly 50%, relapse with single or multiple metastases and die for lung cancer (5-year survival rate equal to 56%) (6) . Having in mind these poor outcomes and lung cancer screening implementation in the very nextfuture, which will increase fraction of surgical patients, is easy to gauge the urgent need of peri-operative (adjuvant and neo-adjuvant) treatment strategies capable to really impact on long-term patients' survival benefit (7) (8) (9) . That said, current standard approach in the adjuvant setting is still represented by cisplatin-doublet chemotherapy, based on a survival benefit of 5.4% at 5 years follow up (10) .
Genomic complexity of lung adenocarcinoma is well characterized, supporting the evidence of different tumor entities with different biology, natural history and clinical behavior (11) . Within oncogene-addicted tumors itself, fusions-positive lung cancers retain peculiar aspects, compared to mutation-driven cancers (e.g., EGFR+) (12, 13) . Thus, a deep understating of ALK fusionsrelated clinical implications in early stage of the disease is mandatory, to precisely determine their prognostic relevance and, consequently, promote therapeutic strategies' implementation that could impact on PFS and, more relevant, on overall survival (OS).
ALK rearrangement frequency (early and late stage)
Since the discovery of ALK translocations (mainly involving EML4 as partner gene) in NSCLC, this molecular event appeared to be a relative infrequent phenomenon, detectable in 2-7% of patients (14) . Notably, almost all the dataset screened for ALK gene fusions were composed of surgically treated patients, having enough tumor tissue for comprehensive molecular analyses (15) (16) (17) . In these and other surgical series ALK rearrangements are seldom identified, reporting a low frequency (<5% in more than 300 samples), whilst percentage of positivity impressively increases looking at the advanced (stage IV) population, rising at 18% (18, 19) . Conversely, EGFR mutations detection remains around 15% across different disease stages (20, 21) . Multiple factors may justify this different behavior. A possible explanation is that ALK translocations, once associated with other genetic disrupting events, drive an aggressive metastasizing tumor phenotype, leading to its identification only at late stages of the disease. Supporting this hypothesis, also early stages ALK+ lung cancers appeared to be more spread than what initially thought: a recent retrospective analysis, performed on resected lung adenocarcinoma with clinical N0 (absence of computed tomography or positron emission tomography detectable lymph node involvement), revealed an higher percentage of pathological N1 or N2 stage (37%) in ALK+ cases compared to other subgroups (EGFR+, KRAS+ or WT) (22) . ALK+ lung cancer patients are younger, never or light smoker, diagnosed mainly on advanced stage of the disease, bearing adenocarcinoma histology with peculiar aspects: solid or sheet-like pattern, with "signet-ring" cells and invasive mucinous aspects, similar to other fusionpositive subgroups (i.e., ROS+ or RET+) (13, (17) (18) (19) ; thus, identifying a subgroup of tumors with morphological aspects denoting itself a more aggressive phenotype (23, 24) .
Different authors investigated the prognostic relevance of oncogene-addiction in early-stage lung cancers, but a general consensus has not been reached due to conflicting results. Identification of the right comparator group seems to be relevant: results of an European platform screening, conducted mainly in a smoker population, identifies ALK positivity (either by IHC or FISH) as predictor of better OS, whereas in other studies, evaluating never-smoker populations, the presence of ALK translocations resulted to be associated with poor disease free survival (DFS) (25) (26) (27) . Similarly, other studies conducted on resected lung cancers highlight the association between ALK positivity and reduced recurrence free survival (RFS) or DFS compared to EGFR+ patients, although no differences in OS have been reported (13, 28, 29) . Multiple factors can potentially jeopardize the prognostic interpretation of ALK fusions in surgical patients: retrospective nature of these studies, heterogeneity of comparator (smokers/never-smokers, oncogenic drivers, different stages) and limited number of ALK+ patients. Extended follow-up, prospective and wider validation analyses, including different oncogene-addicted subgroups, could corroborate the evidence of a negative clinical impact of ALK gene translocations. Nevertheless, the undoubted higher number of disease recurrences in this patients' subgroup spurs scientific community to implement peri-operative strategies aiming to a better disease control (9, 30) .
Data on ALK inhibitors in the metastatic setting
Multiple ALK inhibitors are nowadays available in the clinical arena for advanced ALK+ lung cancer patients. Even though large clinical data are available for each compound and molecular mechanisms of resistance have been depicted, nevertheless a clear sequential strategy of administration is still missing.
Initially, crizotinib (Xalkori ® ), a first generation ALK/ ROS1 inhibitor active also against c-MET, was approved by FDA in 2011 and EMA in 2012 as standard treatment for lung cancers harboring ALK fusions, identified through a companion diagnostic assay. Standard drug dosage is 250 mg bid, based on results of randomized phase III trial Profile 1014, for both patients progressing to chemotherapy or treatment-naïve (3, 31) .
Ceritinib (Zykadia ® ) was approved by FDA in 2014, and EMA in 2015, for ALK+ patients progressing or intolerant to crizotinib due to an improved PFS compared to chemotherapy (5.4 vs. 1.6 months) (32); moreover, based on ASCEND-4 trial's results, ceritinib got the reimbursement as first-line option (33) . Initial indication was of 750 mg once daily in fasting patients, but recent ASCEND-8 results reported equal efficacy and an improved tolerability at 450 or 600 mg once daily with a low-fat meal (34) .
Alectinib (Alecensa ® ), a potent and selective ALK/ RET inhibitor, was initially approved in 2015 for patients progressing or intolerant to crizotinib therapy, based on early results of a Japanese phase I-II clinical study (35, 36) . In 2017, phase III ALEX trial results, as above reported, pushed the alectinib approval in first-line setting, at dosage of 600 mg bid, for ALK+ patients reporting a better toxicity profile compared to other TKI and an overwhelming PFS (1, 4) .
Brigatinib (Alunbrig ®) , an ALK and mutated EGFR inhibitor, received an accelerated approval by FDA in 2017 and EMA in 2018 as second line treatment for ALK+ patients, at dosage of 90 mg daily in a run-in phase of 7 days and after at 180 mg daily (37) . Last year have been published results of phase III ALTA-1L trial confirming a superior activity of brigatinib versus crizotinib as upfront treatment in ALK+ patients (2) .
Lastly, lorlatinib (Lorbrena ® ), a third generation ALKi with a high affinity for ALK and ROS-1, had recently got approval by FDA in 2018 and EMA in 2019 as third line treatment for patients who received crizotinib and at least one more compound or as second line option for patients progressing to second-generation ALKi administered upfront (38) . However, in different European countries still remain available only under compassionate use. Ongoing phase III trial is evaluating the activity of this more potent compound as initial therapeutic strategy.
Efforts and challenges exploring adjuvant ALK inhibitors
If diverse efforts have been applied to understand EGFR inhibitors' role in the adjuvant setting, clinical trials in the ALK+ disease scenario are much more limited (39) (40) (41) . Currently recruiting studies in adjuvant setting for ALK-rearranged patients are two phase III clinical trials: ALCHEMIST (NCT02194738) and ALINA (NCT03456076). The first one, taking advantage of wide genetic screening, enrolls stage IB (T ≥4 cm)-IIIA surgical treated patients after completion of standard of care treatments (chemotherapy and/or radiotherapy). ALK+ patients are randomized to receive crizotinib (at classical schedule of 250 mg bid) versus observation, up to 24 months of treatment, in absence of disease progression or unacceptable toxicities. Other two experimental arms contemplate erlotinib for EGFR mutated patients and nivolumab for double negative subgroup. OS is the first endpoint and DFS and Safety are secondary objectives (42) . The latter, ALINA, is a more recent randomized phase III trial designed to directly compare alectinib administration versus gold-standard treatment in ALK+ patients, histologically confirmed as IB (T ≥4 cm) to IIIA stage and surgically resected at 4-12 weeks before the enrollment. Stage IIIA(N2) patients potentially candidates to radiotherapy are not included (being considered a confounding high-risk subgroup). The experimental arm requires continuous therapy with alectinib at classical schedule of 600 mg bid for 24 months, whilst in the control arm patients receive platinum-based chemotherapy for 4 cycles. Primary endpoint is DFS and, secondary objective OS. Furthermore, alectinib's pharmacokinetic features and possible adverse events are monitored during administration. The study, started in 2018, will be terminated in 2023, with an estimated sample of 255 patients (43) .
Alectinib, even more than crizotinib, is a well-tolerated therapy with a spectrum of adverse events typical of TKI and more manageable than chemotherapy, although rare serious adverse events may happen with new-generation TKI (1, 44, 45) . Therefore, a long-course treatment in completely resected ALK+ patients is worthwhile if a real impact on long-term survival is obtained. As observed for EGFR+ lung cancer patients, initial exciting results, in terms of disease recurrence control, are impermanent and survival curves tend to converge and overlap after 4 years follow-up (39, 40) . Consequently, major results in adjuvant approaches could be attested only by mature and complete OS data, as the ALCHEMIST trial should provide (42) . Multiple ALK inhibitors are available in the clinical arena and one puzzling issue, for peri-operative management of ALK+ NSCLC, is the selection of the correct TKI to be administered, in order to gain the best clinical benefit avoiding dangerous adverse events and disease's molecular hijacking (46) . Development of genotype-directed clinical trials in the adjuvant setting is encumbered by the need of large patients recruitment, the identification of a specific targetable alteration in early-stage tumors and the timeframe of long-term follow-up, making them often less attractive. Therefore, clinical trials exploring drugs' efficacy in this setting need to be carefully planned; for instance, the ALCHEMIST trial has been designed in order to overcome these limitations (42) . One major challenge is due to the identification of quite rare molecular alterations in earlystage tumors, avoiding positive patients' leak. Taking advantage of modern next-generation platforms, which give the opportunity of multi-gene analyses both at DNA and RNA level, we should consider the opportunity of screen the entire population of resected lung tumors in order to get a comprehensive molecular sub-stratification. With these data available at baseline, clinicians will be able to more easily and largely enroll patients within genotyperestricted adjuvant trials.
Biological challenges of adjuvant therapy
As we learned from experience acquired targeting ALK oncogene in the advanced stage, TKIs are able to inhibit cell proliferation, hindering tumor growth in terms of dimension and number of metastatic sites, rather than eradicate the disease. Thus, residual neoplastic cells persist and eventually become resistant to targeted therapies (47, 48) . Drug-sensitive tumor cells can have growth flare at therapy discontinuation or respond again at re-treatment, meaning that these cells can be curbed, but non totally killed by TKI, even of more potent-generation. This growth-suppressant property of ALKi poses a major concern about ALK targeting as adjuvant treatment, whose aim is to eliminate microscopically residual disease. It is more beneficial to treat patients with undetectable tumor cells or at evidence of macroscopic relapse? Does TKI adjuvant treatment have the same long-term survival impact than administration at disease recurrence? Reasonably, only OS data of ongoing clinical trials will answer clear-cutting to these questions, ironing out any doubts about worthiness of adjuvant therapy in oncogeneaddicted patients (49) .
Neoplastic lesions are composed of heterogeneous cells population and, under pharmacological pressure imposed by TKI, clones with different biological behaviors emerge. Among them, a subpopulation of cells is able to enter in a reversible cell-cycle arrest phase becoming "dormant" or "quiescent". In this state, cancer cells not longer affected by TKI exposure, tend to acquire other genetic mutations, to undergo epigenetic modifications and to hijack tumor microenvironment eluding immune-control (50) (51) (52) (53) . Thus, persister/tolerant cells represent a reservoir of resistance mechanisms to targeted therapies and, once these take over control, tumor lesions start to grow again (48) . Unfortunately, little is known about underpinning molecular events driving this "persistent" phenotype and whether ALKtargeting adjuvant therapies may cause accumulation of this cancer cells subset, altering biological history of the disease, is still to be defined. Relevant insights will be gained through clinical trials, ongoing or planned (i.e., NCT03088930 and PROMISE trials), in the neo-adjuvant setting, taking advantage of the opportunity to analyze residual tumor tissues after TKI exposure (8, 30, 54) . A deep characterization of residual tumor cells and associated tumor microenvironment represents a unique chance to deeply study TKI-induced early molecular alterations driving future resistance to targeted therapies.
Recent advances in circulating tumor DNA (ctDNA) detection and analyses are changing clinical approach for cancer patients, even in the setting of early stage NSCLC; it's possible to trace molecular evolution (i.e., identification of resistance mutations) influencing therapeutic strategies in the advance stage, follow clonal heterogeneity of cancer, help early cancer stage screening and also detect minimal residual disease (MRD) in resected patients S294 (55) (56) (57) (58) (59) (60) (61) (62) . Identification of MRD has been identified as a robust marker of impending disease recurrence both in hematological and solid tumors (63) (64) (65) , therefore helping in risk stratification of early stage patients (Figure 1) . With new available technologies and the application of next generation sequencing on surgical specimens is possible to design patient-specific MRD panel, covering specific tumorassociated mutations rather than the entire genome (65). This implies multiple questions in the management of early stage ALK+ and other oncogene-addicted lung cancer patients: adjuvant therapy should start immediately to all patients after surgery or only at MRD positivity? Should it be monitored with blood-based targeted genomic changes and how often checked? Which is the right threshold (as absolute number or raising rate) defining patients that have to be treated? Are there specific MRD+ positive subgroups with higher risk of relapse (i.e., EML4-ALK fusion variant V3 and/or TP53 co-mutations) (66)?
The limited available experience in the adjuvant setting, mainly acquired on EGFR+ patients, is based on second-generation inhibitors and little is now about last-generation, more potent TKI and their influence on tumor's biology; data from ongoing trials will provide relevant insights (41, 43) . Adjuvant treatments are administered for a specific timeframe (i.e., 24 months) and resistance mechanisms may not suddenly emerge. Nevertheless, drug-tolerant cell clones can proliferate and potentially hijack tumor evolution generating resistant phenotypes. Future perspectives should take in consideration also alternative strategies in order to prevent these phenomena: safe combination of drugs (given together or as switching therapies) targeting different signalling pathways; intermitting administrations which may control tumor heterogeneity and development of resistant clones; reprogramming agents (e.g., epigenetic modifiers) able to interfere with tumor cells adaptation and tumorstroma interaction (67,68) ( Figure 1) .
The bet of adjuvant therapies with targeted agents in oncogene addicted NSCLC is to really improve chances of cure ensuring low risks for patients: minimize TKI-related adverse events and avoid molecular disruption 
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of ALK-rearranged disease, preserving future therapeutic opportunities.
